![]() ![]() In the other, Decode researchers ran samples from 35,559 Icelandic subjects on the 5,000-protein version of the SomaScan platform. ![]() In one, researchers at the UK Biobank ran samples from 47,151 European subjects on Olink's Explore 1536 platform (which measures 1,459 proteins). The Decode study, which was published last month as a BioRxiv preprint, looked at results from a pair of large-scale proteogenomic projects performed using either of the two platforms. Specifically, it found that roughly 36 percent of the protein-phenotype links were observed by only one of the two systems, indicating, the authors wrote, "that both techniques capture distinct aspects of protein biology." That study did not seek to assess which, if either, of the two platforms was superior but did see substantial divergence between their data. Perhaps the most notable is a project published last year in Nature Communications by a University of Cambridge-led team that included SomaLogic Chief Medical Officer Stephen Williams. SomaLogic's SomaScan measures roughly 7,000 proteins using the company's Somamer reagents, a form of aptamer.įew studies have directly compared the two platforms. Olink's Explore platform measures up to 3,000 proteins via the company's proximity extension assay technology, which uses pairs of antibodies linked to DNA strands that are brought into proximity when the antibodies bind and are then extended by a DNA polymerase, creating a new sequence that can be used as a surrogate marker for the target protein. Uppsala, Sweden-based Olink and Boulder, Colorado-based SomaLogic are the two dominant providers of affinity-based assays for high-throughput, highly multiplexed plasma proteomics. Scientists not involved with the work, as well as a SomaLogic official, have disputed the study's findings, claiming flaws in its experimental design and procedures and calling into question whether the data presented in fact demonstrates the superiority of Olink's system. NEW YORK – A recent study from Decode Genetics has sparked controversy in the world of plasma proteomics by suggesting that Olink's Explore platform outperforms SomaLogic's SomaScan system. Advances in Clinical Genomics Profiling.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |